Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Shanghai Henlius Biotech, Inc. has announced a delay in sending out the Composite Document for its proposed privatization by Fosun New Medicine, citing the need for more time to fulfill pre-conditions required for the merger. The company is working towards obtaining necessary governmental and regulatory approvals and has received indication from regulatory authorities that an extension for document dispatch may be granted up to 7 May 2025. Further updates will be provided as the situation develops and as compliance with the Takeovers Code is maintained.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.
